U.S. Secretary of State Mike Pompeo says Huawei CFO Meng Wanzhou, who is under house arrest in Canada and facing extradition to America, is not a bargaining chip in the trade...Technologyread more
Boris Johnson will be meeting President Donald Trump to discuss a potential post-Brexit trade deal just as he tries to court EU leaders for a new withdrawal agreement.World Politicsread more
Arturo Estrella has a message for recession naysayers: It could hit sooner than you think.Marketsread more
Accountants in Hong Kong took to the streets on Friday to call for the government to accept five demands of the people, including the complete withdrawal of a now-suspended...China Politicsread more
Recent trade friction between the two Asian powerhouses has morphed into a dispute with political implications that go far beyond the region.Asia Politicsread more
Fed Chairman Jerome Powell faces the tough challenge of presenting a unified voice on Fed policy from the most divided Fed in years.Market Insiderread more
Local governments commonly share single service providers, making many vulnerable at once. On top of this, ransomware has often been used to mask more targeted, malicious...Technologyread more
Bank Indonesia on Thursday cut its key policy rate by 25 basis points to 5.5% to support growth amid an increasingly fragile global economy.Central Banksread more
Meanwhile, investors look ahead to Fed Chair Jerome Powell's speech at a yearly central banking symposium in Jackson Hole, Wyoming.Asia Marketsread more
The office has long been a breeding ground for budding romances. But actively going into business with your other half is another thing entirely.Successread more
Salesforce released its first earnings report since its $15.3 billion acquisition of Tableau Software, the company's largest deal ever.Technologyread more
Shares of Ziopharm Oncology fell nearly 14 percent Friday after a cancer patient died soon after being injected with the company's experimental cancer therapy.
The Boston-based biopharmaceutical company, which owns and acquires a portfolio of cancer therapies, is running an experimental treatment on patients with an aggressive primary brain tumor. This type of cancer, called Glioblastoma, has one of the lowest survival rates among cancers, the company said.
"These patients are all, unfortunately, medically fragile," Ziopharm said in a statement. "The first two patient deaths, which occurred 6.7 months and 3.9 months after treatment, were unrelated to study drug."
This week, a third death was reported. The company said it is "collecting and analyzing information in order to properly and timely report it to the FDA."
The patient died of an intracranial hemorrhage, which happened after the patient had been discharged from the treatment center.
"This is an isolated case, and there have been no reported related instances of brain hemorrhage in any pervious cohort or prior studies ," the company said.
Shares traded near $4.89, and are down more than 18 percent this week and 40 percent year to date.